Session R.A. II
- SEC CIK
- 0001701846
No open-market purchases or sales filed in the past year.
Current role at each company
- TSHA Taysha Gene Therapies, Inc.10% Owneras of Jul 14, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Session R.A. II as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 14, 2023 (view filing) | Jul 12-13 | 2 days | Session R.A. II10% Owner | SSale | −85.9K | $0.7094 | −$60.9K | −1.0%8.87M after | 2 lots |
| Jun 26, 2023 (view filing) | Jun 22-23 | 4 days | Session R.A. II10% Owner | SSale | −28.6K | $0.70 | −$20.0K | −0.3%8.96M after | 2 lots |
| Jun 22, 2023 (view filing) | Jun 20-21 | 2 days | Session R.A. II10% Owner | SSale | −434.6K | $0.7068 | −$307.2K | −4.6%8.99M after | 2 lots |
| Dec 8, 2021 (view filing) | Nov 23 | 15 daysLate | Session R.A. IIPresident and CEO | PPurchase | +42.5K | $12.44 | +$529.1K | +0.5%9.19M after | 2 lots |